Sangamo Therapeutics Inc (NASDAQ:SGMO) saw a large drop in short interest during the month of April. As of April 30th, there was short interest totalling 13,536,304 shares, a drop of 11.0% from the April 15th total of 15,208,698 shares. Based on an average daily volume of 1,287,488 shares, the short-interest ratio is presently 10.5 days. Currently, 11.8% of the shares of the company are sold short.

SGMO opened at $9.46 on Friday. The company has a market capitalization of $1.09 billion, a P/E ratio of -13.51 and a beta of 2.89. Sangamo Therapeutics has a 12 month low of $6.26 and a 12 month high of $19.25. The company has a quick ratio of 3.98, a current ratio of 3.98 and a debt-to-equity ratio of 0.04.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.14). The business had revenue of $8.07 million during the quarter, compared to the consensus estimate of $27.21 million. Sangamo Therapeutics had a negative return on equity of 24.67% and a negative net margin of 113.03%. On average, equities analysts expect that Sangamo Therapeutics will post -1.39 earnings per share for the current year.

Several brokerages have recently issued reports on SGMO. BidaskClub upgraded shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 2nd. ValuEngine downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, February 4th. Finally, Wedbush set a $11.00 price objective on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a report on Tuesday, May 14th. One analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $16.00.

In other news, CFO Kathy Yi sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $10.00, for a total transaction of $50,000.00. Following the completion of the sale, the chief financial officer now owns 30,512 shares in the company, valued at approximately $305,120. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last 90 days, insiders have sold 20,000 shares of company stock valued at $210,550. 1.30% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SGMO. Bank of New York Mellon Corp boosted its holdings in Sangamo Therapeutics by 1.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 454,735 shares of the biopharmaceutical company’s stock worth $7,708,000 after buying an additional 7,472 shares during the period. Dimensional Fund Advisors LP bought a new position in Sangamo Therapeutics in the 3rd quarter valued at $3,755,000. JPMorgan Chase & Co. boosted its holdings in Sangamo Therapeutics by 8.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 105,711 shares of the biopharmaceutical company’s stock valued at $1,792,000 after purchasing an additional 7,817 shares during the period. Neuberger Berman Group LLC bought a new position in Sangamo Therapeutics in the 3rd quarter valued at $309,000. Finally, Teachers Advisors LLC boosted its holdings in Sangamo Therapeutics by 7.9% in the 3rd quarter. Teachers Advisors LLC now owns 1,000,485 shares of the biopharmaceutical company’s stock valued at $16,958,000 after purchasing an additional 73,264 shares during the period. 56.64% of the stock is owned by institutional investors.

WARNING: “Sangamo Therapeutics Inc (SGMO) Short Interest Update” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.thecerbatgem.com/2019/05/24/sangamo-therapeutics-inc-sgmo-short-interest-update.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

See Also: The primary rules of Elliott Wave theory

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.